Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 7/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | BRD4 | O60885 | 4/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1773025 | 0.96 | HTR6 (0.45) | HTR6ACHEBRD4AGTR1MET | |
| SCHEMBL1772298 | 0.83 | HTR6 (0.46) | HTR6ACHEBRD4 | |
| SCHEMBL1772423 | 0.81 | BRD4 (0.52) | HTR6BRD4AGTR1METTNFSF11 | |
| SCHEMBL1772606 | 0.80 | BRD4 (0.44) | HTR6BRD4AGTR1METALDH1A1 | |
| SCHEMBL1772583 | 0.80 | AGTR1 (0.43) | BRD4AGTR1METTNFSF11ALDH1A1 | |
| SCHEMBL1772515 | 0.80 | BRD4 (0.54) | HTR6BRD4AGTR1METTNFSF11 | |
| SCHEMBL1772103 | 0.78 | HTR6 (0.48) | HTR6BRD4 | |
| SCHEMBL1773806 | 0.78 | HTR6 (0.53) | HTR6ACHEMET | |
| SCHEMBL1772311 | 0.76 | AGTR1 (0.39) | HTR6BRD4AGTR1METTNFSF11 | |
| SCHEMBL25422502 | 0.74 | HTR6 (0.40) | HTR6ACHEBRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338452-B2 | Raf inhibitor compounds and methods of use thereof | ARRAY BIOPHARMA INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Bio Pharma Inc. (US) | 2011-05-12 | — | — | US | disclosed |
| EP-2265608-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009111278-A2 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110110889-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | HTR6 4804/4885ACHE 4810/4885BRD4 3329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.